A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

NCT07438444 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety of the medication tirzepatide in adults in India who have either type 2 diabetes or obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 344 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-02 · est. completion 2027-10

Where 21 sites · India

What this study is testing ClinicalTrials.gov NCT07438444 ↗

Description as written by the study sponsor.

The main purpose of this study is to measure the safety and efficacy of tirzepatide in adult participants in India who have type 2 diabetes or who have obesity or overweight without type 2 diabetes. Participation in the study will last about 46 weeks.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC

Main thing measured	Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2, Obesity, Overweight
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07438444 ↗